BiMix Phentolamine/Papaverine 1 mg/30 mg/mL
Lack of Assurance of Sterility
Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.
14,543 recalls, newest first.
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Lack of Assurance of Sterility
Failed Stability Specifications; out-of specification value for homogeneity / phase separation.
Microbial Contamination of Non-Sterile Products: bulk solution tested positive for the presence of the bacteria, Burkholderia cepacia.
Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.
Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.
Superpotent
Lack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.
Lack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.
Presence of Foreign Tablets/Capsules; report of Amlodipine Tablets found in 1000 count bottles of Metformin Hydrochloride Tablets USP
Lack of Assurance of Sterility: Complaints of broken tips on the ampules.
CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.
CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.
CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.
CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.
CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures
CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures
CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures
CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures
CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures